Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials.

clinical trials cooperative groups health policy industry funding

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Sep 2020
Historique:
received: 01 08 2020
revised: 11 09 2020
accepted: 11 09 2020
entrez: 19 9 2020
pubmed: 20 9 2020
medline: 20 9 2020
Statut: epublish

Résumé

The pace of clinical trial data generation and publication is an area of interest within clinical oncology; however, little is known about the dynamics and covariates of time to reporting (TTR) of trial results. To assess these, ClinicalTrials.gov was queried for phase three clinical trials for patients with metastatic solid tumors, and the factors associated with TTR from enrollment completion to publication were analyzed. Based on the 319 included trials, cooperative-group-sponsored trials were reported at a slower rate than non-cooperative-group trials (median 37.5 vs. 31.0 months;

Identifiants

pubmed: 32947844
pii: cancers12092636
doi: 10.3390/cancers12092636
pmc: PMC7563891
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : P30 CA016672
Pays : United States

Références

JAMA. 2015 Dec 15;314(23):2566-7
pubmed: 26670975
J Natl Cancer Inst. 2013 Jul 3;105(13):954-9
pubmed: 23776198
N Engl J Med. 2016 Dec 8;375(23):2263-2271
pubmed: 27959693
JAMA Intern Med. 2014 Oct;174(10):1695-6
pubmed: 25156272
Lancet. 2020 Feb 1;395(10221):361-369
pubmed: 31958402
JAMA Oncol. 2019 Jun 3;:
pubmed: 31158272
J Clin Oncol. 2009 Apr 10;27(11):1761-6
pubmed: 19255315
J Clin Oncol. 2013 Sep 20;31(27):3432-8
pubmed: 23960185
BMJ. 2003 May 31;326(7400):1167-70
pubmed: 12775614
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Clin Oncol. 2006 Oct 1;24(28):4545-52
pubmed: 17008693
JCO Oncol Pract. 2020 Apr;16(4):e324-e332
pubmed: 32048941
Eur J Cancer. 2020 Sep;136:176-185
pubmed: 32702645
J Clin Oncol. 2016 Nov 1;34(31):3796-3802
pubmed: 27601549
J Clin Oncol. 2013 Sep 20;31(27):3312-4
pubmed: 23960175
J Natl Cancer Inst. 2014 Sep 04;106(9):
pubmed: 25190726
JAMA Intern Med. 2019 May 1;179(5):642-647
pubmed: 30933235
JAMA Netw Open. 2019 Jan 4;2(1):e186875
pubmed: 30644967

Auteurs

Timothy A Lin (TA)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Department of Radiation Oncology and Molecular Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 401 N. Broadway Baltimore, MD 21287, USA.

Clifton David Fuller (CD)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Vivek Verma (V)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Walker Mainwaring (W)

Lankenau Medical Center, 100 E Lancaster Ave, Wynnewood, PA 19096, USA.

Andres F Espinoza (AF)

Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.

Austin B Miller (AB)

McGovern Medical School, The University of Texas Health Science Center, 7000 Fannin, Suite 1880, Houston, TX 77030, USA.

Amit Jethanandani (A)

Department of Radiation Oncology, The University of Miami Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Miami, FL 33136, USA.

Dario Pasalic (D)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Prajnan Das (P)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Bruce D Minsky (BD)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Charles R Thomas (CR)

Department of Radiation Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.

David R Fogelman (DR)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Vivek Subbiah (V)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Ishwaria M Subbiah (IM)

Department of Palliative, Rehabilitational, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Ethan B Ludmir (EB)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Classifications MeSH